Haemonetics (HAE) PT Lowered to $108 at Needham & Company; 'CSL Loss a Gut Punch But Not a Knock-Out'
Tweet Send to a Friend
Needham & Company analyst Mike Matson lowered the price target on Haemonetics (NYSE: HAE) to $108.00 (from $158.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
